Search the collection

Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 1
ArticlesPeer ReviewedFull Text
Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study
Author / Creator:Liu, Lulu ; Wang, Lei ; Ding, Yiling ; Zhang, Qilin ; Shu, Yamin
Publisher:England
Journal title:BMJ open, 2025-03, Vol.15 (3), p.e094804
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 2
ArticlesPeer ReviewedFull Text
Cost-effectiveness of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a comparative analysis in China, the United States and Europe
Author / Creator:Sun, Yuyang ; Xu, Kai ; Yao, Hongting ; Wei, Jingxuan ; Ding, Baolong ; Qian, Xiaodan ; Su, Dan ; Gong, Jinhong ; Shang, Jingjing ; Zhang, Lingli ; Li, Xin
Publisher:Cham: Springer International Publishing
Journal title:International journal of clinical pharmacy, 2025-02, Vol.47 (1), p.196-209
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 3
ArticlesPeer ReviewedFull Text
Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China
Author / Creator:Wei, Jingxuan ; Xu, Kai ; Lin, Yingtao ; Liu, Qiang ; Zhou, Chongchong ; Zhang, Pei ; Ma, Rui ; Zhang, Mengdie ; Zhang, Lingli ; Li, Xin
Publisher:Cham: Springer International Publishing
Journal title:International journal of clinical pharmacy, 2024-10, Vol.46 (5), p.1189-1199
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 4
ArticlesPeer ReviewedFull Text
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
Author / Creator:Su, Dan ; Wu, Bin ; Shi, Lizheng
Publisher:United States: American Medical Association
Journal title:JAMA network open, 2021-02, Vol.4 (2), p.e210037-e210037
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 5
ArticlesPeer ReviewedFull Text
Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
Author / Creator:Kobayashi, Masahiro ; Kudo, Masatoshi ; Izumi, Namiki ; Kaneko, Shuichi ; Azuma, Mie ; Copher, Ronda ; Meier, Genevieve ; Pan, Janice ; Ishii, Mika ; Ikeda, Shunya
Publisher:Tokyo: Springer Japan
Journal title:Journal of gastroenterology, 2019-06, Vol.54 (6), p.558-570
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 6
ArticlesPeer ReviewedFull Text
Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis
Author / Creator:Shlomai, Amir ; Leshno, Moshe ; Goldstein, Daniel A
Publisher:United States: Public Library of Science
Journal title:PloS one, 2018-11, Vol.13 (11), p.e0207132-e0207132
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 7
ArticlesPeer ReviewedFull Text
Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis
Author / Creator:Cai, Hongfu ; Lin, Jingwen ; Zhu, Huide ; Zheng, Zhiwei
Publisher:England: British Medical Journal Publishing Group
Journal title:BMJ open, 2024-12, Vol.14 (12), p.e079603
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 8
ArticlesPeer ReviewedFull Text
Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia
Author / Creator:Saiyed, Masnoon ; Byrnes, Joshua ; Srivastava, Tushar ; Scuffham, Paul ; Downes, Martin
Publisher:Cham: Springer International Publishing
Journal title:Clinical drug investigation, 2020-12, Vol.40 (12), p.1167-1176
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 9
ArticlesPeer ReviewedFull Text
Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis
Author / Creator:Cai, Hongfu ; Zhang, Longfeng ; Li, Na ; Zheng, Bin ; Liu, Maobai
Publisher:England: Future Medicine Ltd
Journal title:Journal of comparative effectiveness research, 2020-06, Vol.9 (8), p.553-562
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 10
ArticlesPeer ReviewedFull Text
Disparities in Access to Sorafenib in Communities with Low Socioeconomic Status
Author / Creator:Sarpel, Umut ; Heskel, Marina ; Spivack, John Henry ; Feferman, Yael ; Ang, Celina ; Gany, Francesca
Publisher:United States: Johns Hopkins University Press
Journal title:Journal of health care for the poor and underserved, 2018-01, Vol.29 (3), p.1123-1134
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 11
ArticlesPeer ReviewedFull Text
How patent law reform can improve affordability and accessibility of medicines in South Africa : four medicine case studies
Author / Creator:Moyo, H. ; Tomlinson, C. ; Hu, Y.Q. ; Waterhouse, C. ; Meyer, S.
Publisher:Health and Medical Publishing Group (HMPG)
Journal title:South African medical journal, 2019-06, Vol.109 (6), p.387-391
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.

Search the collection

Export record to excel

Export this record

Export record to excel

Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study

Export this record

Export record to excel

Cost-effectiveness of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a comparative analysis in China, the United States and Europe

Export this record

Export record to excel

Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China

Export this record

Export record to excel

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma

Export this record

Export record to excel

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan

Export this record

Export record to excel

Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis

Export this record

Export record to excel

Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis

Export this record

Export record to excel

Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia

Export this record

Export record to excel

Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis

Export this record

Export record to excel

Disparities in Access to Sorafenib in Communities with Low Socioeconomic Status

Export this record

Export record to excel

How patent law reform can improve affordability and accessibility of medicines in South Africa : four medicine case studies

Refine your search